Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
- Market Dynamics
- Emerging Technologies
- Analysis by Segment
- Regional Analysis
- Conclusion
Chapter 2 Market Overview
- Overview and Market Definition
- Different Microbiomes in Humans
- Microbiome, Human Health and Disease
- Technologies Aiding Microbiome Research
- Culturing and Cultivation
- Strategies for the Development of Microbiome Therapeutics
- Additive Microbiome Therapy
- Modulatory Microbiome Therapy
- Analysis of Macroeconomic Factors
- Geopolitical Factors
- Inflation and Currency Exchange Fluctuations
- Porter's Five Forces Analysis
Chapter 3 Market Dynamics
- Takeaways
- Market Drivers
- Growing Evidence of Microbiome-disease Correlation
- Microbiome-based Diagnostics for Disease Prevention and Monitoring
- Market Restraints
- Challenges in Clinical Trial Design
- Lack of Established Regulatory Frameworks
- High Costs of Microbiome Therapeutics
- Market Opportunities
- Direct-to-Consumer Microbiome Testing
- Drugs and Diagnostics for Lung and Skin Microbiomes
Chapter 4 Regulatory Landscape
- Regulatory Aspects
- North America
- Europe
- Asia-Pacific
Chapter 5 Emerging Technologies
- Takeaways
- Emerging Technologies
- Microbial Ecosystem Therapeutics
- Metatranscriptome Sequencing
- Genetically Modified Microbiome Therapeutics
- Combination and Adjuvant Therapies with Microbiome-based Drugs
- Novel Preclinical Models
Chapter 6 Market Segmentation Analysis
- Segmentation Breakdown
- Market Analysis by Type
- Microbiome-based Drugs
- Market Analysis by Application
- Infectious Diseases
- GI Disorders
- Metabolic Disorders
- Cancer
- Other Diseases
- Market Analysis by End User
- Hospitals and Clinics
- Research Institutions
- Pharmaceutical Companies
- Geographic Breakdown
- Market Analysis by Region
- North America
- Europe
- Asia-Pacific
- South America
- Middle East and Africa
Chapter 7 Competitive Intelligence
- Takeaways
- Company Share Analysis
- Competitive Analysis
- Venture Funding and Investment Landscape
- Recent Developments
Chapter 8 Sustainability in the Human Microbiome-based Drugs and Diagnostics Industry: An ESG Perspective
- Introduction to ESG
- ESG Risk Ratings
- Concluding Remarks
List of Tables
Summary Table: Global Market for Human Microbiome-based Drugs and Diagnostics, by Region, Through 2030
Table 1: Technology for Microbiome Research
Table 2: Diseases Associated with Microbiome Dysbiosis
Table 3: Microbiome-based Drug Nomenclature
Table 4: Global Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030
Table 5: Global Market for Human Microbiome-based Drugs, by Route of Administration, Through 2030
Table 6: Global Market for Human Microbiome-based Drugs, by Region, Through 2030
Table 7: Global Market for Human Microbiome-based Drugs, by Rectal Route of Administration, by Region, Through 2030
Table 8: Global Market for Human Microbiome-based Drugs, by Oral Route of Administration, by Region, Through 2030
Table 9: Global Market for Human Microbiome-based Diagnostics, by Region, Through 2030
Table 10: Global Market for Human Microbiome-based Diagnostics, by Product Type, Through 2030
Table 11: Global Market for Human Microbiome-based Diagnostics Reagents and Kits, by Region, Through 2030
Table 12: Global Market for Human Microbiome-based Diagnostic Instruments, by Region, Through 2030
Table 13: Global Market for Human Microbiome-based Drugs and Diagnostics, by Application, Through 2030
Table 14: Global Market for Human Microbiome-based Drugs and Diagnostics for Infectious Diseases, by Region, Through 2030
Table 15: Global Market for Human Microbiome-based Drugs and Diagnostics for GI Disorders, by Region, Through 2030
Table 16: Global Market for Human Microbiome-based Drugs and Diagnostics for Metabolic Disorders, by Region, Through 2030
Table 17: Global Market for Human Microbiome-based Drugs and Diagnostics for Cancer, by Region, Through 2030
Table 18: Microbiome-based Drugs in the Pipeline for Cancer Therapy
Table 19: Global Market for Human Microbiome-based Drugs and Diagnostics for Other Diseases, by Region, Through 2030
Table 20: Global Market for Human Microbiome-based Drugs and Diagnostics, by End User, Through 2030
Table 21: Global Market for Microbiome-based Drugs and Diagnostics for Hospitals and Clinics, by Region, Through 2030
Table 22: Global Market for Microbiome-based Drugs and Diagnostics for Research Institutions, by Region, Through 2030
Table 23: Global Market for Microbiome-based Drugs and Diagnostics for Pharmaceutical Firms, by Region, Through 2030
Table 24: Global Market for Human Microbiome-based Drugs and Diagnostics, by Region, Through 2030
Table 25: North American Market for Human Microbiome-based Drugs and Diagnostics, by Country, Through 2030
Table 26: North American Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030
Table 27: North American Market for Microbiome-based Drugs, by Route of Administration, Through 2030
Table 28: North American Market for Microbiome-based Diagnostics, by Product Type, Through 2030
Table 29: North American Market for Microbiome-based Drugs and Diagnostics, by Application, Through 2030
Table 30: North American Market for Microbiome-based Drugs and Diagnostics, by End User, Through 2030
Table 31: European Market for Human Microbiome-based Drugs and Diagnostics, by Country, Through 2030
Table 32: European Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030
Table 33: European Market for Microbiome-based Drugs, by Route of Administration, Through 2030
Table 34: European Market for Microbiome-based Diagnostics, by Product Type, Through 2030
Table 35: European Market for Microbiome-based Drugs and Diagnostics, by Application, Through 2030
Table 36: European Market for Microbiome-based Drugs and Diagnostics, by End User, Through 2030
Table 37: Asia-Pacific Market for Human Microbiome-based Drugs and Diagnostics, by Country, Through 2030
Table 38: Asia-Pacific Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030
Table 39: Asia-Pacific Market for Microbiome-based Drugs, by Route of Administration, Through 2030
Table 40: Asia-Pacific Market for Microbiome-based Diagnostics, by Product Type, Through 2030
Table 41: Asia-Pacific Market for Microbiome-based Drugs and Diagnostics, by Application, Through 2030
Table 42: Asia-Pacific Market for Microbiome-based Drugs and Diagnostics, by End User, Through 2030
Table 43: South American Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030
Table 44: South American Market for Microbiome-based Drugs, by Route of Administration, Through 2030
Table 45: South American Market for Microbiome-based Diagnostics, by Product Type, Through 2030
Table 46: South American Market for Microbiome-based Drugs and Diagnostics, by Application, Through 2030
Table 47: South American Market for Microbiome-based Drugs and Diagnostics, by End User, Through 2030
Table 48: MEA Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030
Table 49: MEA Market for Microbiome-based Drugs, by Administration Route, Through 2030
Table 50: MEA Market for Microbiome-based Diagnostics, by Product Type, Through 2030
Table 51: MEA Market for Microbiome-based Drugs and Diagnostics, by Application, Through 2030
Table 52: MEA Market for Microbiome-based Drugs and Diagnostics, by End User, Through 2030
Table 53: Competitive Analysis of Human Microbiome-based Diagnostics Market
Table 54: Venture Funding in the Human Microbiome-based Drugs and Diagnostics Market, 2024
Table 55: Recent Developments in the Human Microbiome-based Drug and Diagnostics Market, 2022-2025
Table 56: ESG Goals of Human Microbiome-based Drugs and Diagnostics Companies
Table 57: ESG Risk Ratings for Human Microbiome-based Drugs and Diagnostics Firms, 2025
Table 58: Report Information Sources
Table 59: Abbreviations Used in this Report
Table 60: BiomeBank: Company Snapshot
Table 61: BiomeBank: Product Portfolio
Table 62: BiomeBank: News/Key Developments, 2024
Table 63: EnteroBiotix Ltd.: Company Snapshot
Table 64: EnteroBiotix Ltd.: Product Portfolio
Table 65: EnteroBiotix Ltd.: News/Key Developments, 2024
Table 66: Enterome: Company Snapshot
Table 67: Enterome: Product Portfolio
Table 68: Enterome: News/Key Developments, 2022
Table 69: Ferring: Company Snapshot
Table 70: Ferring: Financial Performance, FY 2022 and 2023
Table 71: Ferring: Product Portfolio
Table 72: Ferring: News/Key Developments, 2022 and 2023
Table 73: Genetic Analysis: Company Snapshot
Table 74: Genetic Analysis: Financial Performance, FY 2023 and 2024
Table 75: Genetic Analysis: Product Portfolio
Table 76: Genetic Analysis: News/Key Developments, 2024
Table 77: Illumina Inc.: Company Snapshot
Table 78: Illumina Inc.: Financial Performance, FY 2023 and 2024
Table 79: Illumina Inc.: Product Portfolio
Table 80: Microbiome Insights: Company Snapshot
Table 81: Microbiome Insights: Product Portfolio
Table 82: Microbiome Insights: News/Key Developments, 2024
Table 83: Microbiotica: Company Snapshot
Table 84: Microbiotica: Product Portfolio
Table 85: Microbiotica: News/Key Developments, 2023
Table 86: Nestle Health Science: Company Snapshot
Table 87: Nestle Health Science: Product Portfolio
Table 88: Nestle Health Science: News/Key Developments, 2024
Table 89: Oxford Nanopore Technologies plc: Company Snapshot
Table 90: Oxford Nanopore Technologies plc: Financial Performance, FY 2023 and 2024
Table 91: Oxford Nanopore Technologies plc.: Product Portfolio
Table 92: PacBio: Company Snapshot
Table 93: PacBio: Financial Performance, FY 2023 and 2024
Table 94: PacBio: Product Portfolio
Table 95: PacBio: News/Key Developments, 2025
Table 96: SFA Therapeutics Inc.: Company Snapshot
Table 97: SFA Therapeutics Inc.: Product Portfolio
Table 98: SFA Therapeutics Inc.: News/Key Developments, 2024
Table 99: Thermo Fisher Scientific Inc.: Company Snapshot
Table 100: Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
Table 101: Thermo Fisher Scientific Inc.: Product Portfolio
Table 102: Vedanta Biosciences Inc.: Company Snapshot
Table 103: Vedanta Biosciences Inc.: Product Portfolio
Table 104: Vedanta Biosciences Inc.: News/Key Developments, 2023
Table 105: Emerging Startups
List of Figures
Summary Figure: Global Market Shares of Human Microbiome-based Drugs and Diagnostics, by Region, 2024
Figure 1: Essential Functions of the Human Microbiome
Figure 2: Porter’s Five Forces Analysis of the Human Microbiome-based Drugs and Diagnostics Market
Figure 3: Human Microbiome-based Drugs and Diagnostics Market Dynamics
Figure 4: Diseases and Conditions Associated with Dysbiosis
Figure 5: Global Market Shares of Human Microbiome-based Drugs and Diagnostics, by Type, 2024
Figure 6: Global Market Shares of Human Microbiome-based Drugs and Diagnostics, by Application, 2024
Figure 7: Global Market Shares of Human Microbiome-based Drugs and Diagnostics, by End User, 2024
Figure 8: Global Market Shares of Human Microbiome-based Drugs and Diagnostics, by Region, 2024
Figure 9: North American Market Shares of Human Microbiome-based Drugs and Diagnostics, by Country, 2024
Figure 10: European Market Shares of Human Microbiome-based Drugs and Diagnostics, by Country, 2024
Figure 11: Asia-Pacific Market Shares of Human Microbiome-based Drugs and Diagnostics, by Country, 2024
Figure 12: Company Shares in the Human Microbiome-based Drug Market, 2024
Figure 13: Ferring: Revenue Share, by Business Unit, FY 2023
Figure 14: Ferring: Revenue Share, by Country/Region, FY 2023
Figure 15: Genetic Analysis: Revenue Share, by Business Unit, FY 2024
Figure 16: Genetic Analysis: Revenue Share, by Country/Region, FY 2024
Figure 17: Illumina Inc.: Revenue Share, by Business Unit, FY 2024
Figure 18: Illumina Inc.: Revenue Share, by Country/Region, FY 2024
Figure 19: Oxford Nanopore Technologies plc: Revenue Share, by Business Unit, FY 2024
Figure 20: Oxford Nanopore Technologies plc: Revenue Share, by Country/Region, FY 2024
Figure 21: PacBio: Revenue Share, by Business Unit, FY 2024
Figure 22: PacBio: Revenue Share, by Country/Region, FY 2024
Figure 23: Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2024
Figure 24: Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2024
